DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: High Grade Sarcoma

Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT)
Diagnostic Test: MRI

First Posted Date: 2022-03-29

Last Posted Date: 2025-05-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 43

Registration Number: NCT05301283

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Other: Autologous Stem Cell Transplant
Drug: Immunomodulatory Agent
Drug: Proteasome Inhibitor

First Posted Date: 2022-03-09

Last Posted Date: 2025-02-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 69

Registration Number: NCT05271630

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Preop fSRS for Resectable Brain Metastases

Phase 2

Active, not recruiting

Conditions: Brain Metastases
Brain Lesion

Interventions: Radiation: Hypofractionated Stereotactic Radiosurgery

First Posted Date: 2022-03-04

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 49

Registration Number: NCT05267587

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Prostate Cancer
Prostate Cancer

Interventions: Drug: Luteinizing Hormone Releasing Hormone
Drug: New Hormonal Agent
Drug: Docetaxel
Drug: Tislelizumab

First Posted Date: 2022-01-12

Last Posted Date: 2025-05-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT05189457

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

Phase 2

Active, not recruiting

Conditions: MDS
Myeloproliferative Neoplasm
Chronic Neutrophilic Leukemia

Interventions: Drug: Fedratinib Pill

First Posted Date: 2022-01-04

Last Posted Date: 2025-05-15

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT05177211

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Phase 2

Recruiting

Conditions: Metastatic Uveal Melanoma

Interventions: Drug: Binimetinib
Drug: Belinostat

First Posted Date: 2021-12-27

Last Posted Date: 2025-03-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT05170334

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Phase 1

Terminated

Conditions: Myeloproliferative Neoplasm

Interventions: Drug: Fedratinib Pill

First Posted Date: 2021-11-19

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 12

Registration Number: NCT05127174

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study of Screening Brain MRIs in Stage IV Breast Cancer

Recruiting

Conditions: HER2-positive Breast Cancer
Hormone Receptor-positive Breast Cancer
Triple Negative Breast Cancer

Interventions: Diagnostic Test: Magnetic Resonance Imaging

First Posted Date: 2021-11-10

Last Posted Date: 2025-04-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 170

Registration Number: NCT05115474

Locations: 🇺🇸
Morton Plant Mease- Baycare, Clearwater, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Early Phase 1

Active, not recruiting

Conditions: Rectal Adenocarcinoma

Interventions: Drug: Capecitabine
Radiation: Radiation Therapy
Drug: FOLFOX regimen

First Posted Date: 2021-11-05

Last Posted Date: 2025-03-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT05108428

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Selinexor Pill
Drug: Bevacizumab
Drug: Atezolizumab

First Posted Date: 2021-10-26

Last Posted Date: 2022-10-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 2

Registration Number: NCT05093608

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy